MedTrace Logo

To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets

NCT00913549 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-03-28

No results posted yet for this study

Summary

To demonstrate the relative bioequivalency study of dosage forms of Clemastine 2.68 mg tablets.

Conditions

  • Allergy

Interventions

DRUG

Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)

DRUG

Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)

Sponsors & Collaborators

Principal Investigators

  • James C. Kisicki, M.D. · Harris Laboratories, Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1989-12-31
Primary Completion
1990-01-31
Completion
1990-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00913549 on ClinicalTrials.gov